Cyclacel Pharmaceuticals, Inc.
CYCC
$7.99
-$0.01-0.13%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 10.00K | 14.00K | 43.00K | 74.00K | 80.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 10.00K | 14.00K | 43.00K | 74.00K | 80.00K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 10.00K | 14.00K | 43.00K | 74.00K | 80.00K |
| SG&A Expenses | 7.65M | 8.03M | 5.41M | 6.34M | 6.72M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 10.37M | 12.70M | 12.05M | 15.61M | 20.28M |
| Operating Income | -10.36M | -12.69M | -12.00M | -15.54M | -20.20M |
| Income Before Tax | -5.42M | -7.78M | -11.99M | -15.83M | -20.36M |
| Income Tax Expenses | 986.00K | 572.00K | -782.00K | -2.40M | -2.86M |
| Earnings from Continuing Operations | -6.41 | -8.35 | -11.21 | -13.43 | -17.51 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -6.41M | -8.35M | -11.21M | -13.43M | -17.51M |
| EBIT | -10.36M | -12.69M | -12.00M | -15.54M | -20.20M |
| EBITDA | -10.35M | -12.68M | -12.00M | -15.52M | -20.19M |
| EPS Basic | -253.06 | -423.71 | -423.62 | -344.36 | -172.18 |
| Normalized Basic EPS | -34.73 | -33.79 | -30.15 | -- | -- |
| EPS Diluted | -253.06 | -423.71 | -423.62 | -344.36 | -172.18 |
| Normalized Diluted EPS | -34.73 | -33.79 | -30.15 | -- | -- |
| Average Basic Shares Outstanding | 1.78M | 902.40K | 38.50K | -- | -- |
| Average Diluted Shares Outstanding | 1.80M | 940.20K | 76.30K | 37.80K | 18.90K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -0.64% | -- | -- | -0.37% | -0.57% |